Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 2, 2009

Pfizer Taps Xencor for Antibody-Optimizing Technology

  • Pfizer will evaluate the application of Xencor’s Xtend™ antibody half-life prolongation technology and XmAb® ADCC enhancing technology in several of its discovery projects. In addition, Pfizer has taken a commercial license to Xencor’s technology for one program.

    Xencor will receive an up-front payment and is eligible to considerations based on the successful commercialization of products that incorporate the Xencor technology.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »